Search results

• Ayahuasca
  sometimes medicinal, psychedelic effects. The co-consumption of an MAOI agent is necessary for the combination to work, as the DMT molecule (which is a
  33 KB (3,884 words) - 07:33, 16 November 2023
• Clonidine
  clonidine first saw clinical use in 1966. As the first anti-hypertensive agent with a clearly identifiable central site of action, clonidine has been an
  22 KB (2,932 words) - 13:49, 16 April 2024
• Aniracetam
  Referan, and systematically as N-anisoyl-2-pyrrolidinone) is a nootropic agent belonging to the racetam family of drugs. Although it is one of the first
  11 KB (1,427 words) - 22:01, 24 January 2024
• 2-FA
  it most likely acts primarily as both a dopamine and norepinephrine releasing agent. This means it effectively increases the levels of the norepinephrine
  17 KB (3,024 words) - 17:25, 18 January 2024
• Bufotenin
  with MAOIs, RIMAs, SSRIs, stimulants or any substance which acts as a releasing agent or reuptake inhibitor of monoamine neurotransmitters. Disclaimer: The
  16 KB (2,273 words) - 19:54, 7 April 2024
• MDEA
  ring with other entactogens like MDMA, MDA and MDAI. MDEA acts as a releasing agent and reuptake inhibitor of the monoamine neurotransmitters serotonin
  25 KB (3,654 words) - 23:46, 21 April 2024
• Ephenidine
  com/science/article/pii/S0378427415300333. “Ephenidine: A New Psychoactive Agent with Ketamine-like NMDA Receptor Antagonist Properties.” Neuropharmacology
  25 KB (3,096 words) - 09:43, 10 May 2024
• Scientific information
  content listed within this portal. Agonist Antagonist Reuptake inhibitor Releasing agent Inverse agonist Positive allosteric modulator Negative allosteric modulator
  599 bytes (162 words) - 23:00, 21 April 2024
• Memantine
  Memantine was first synthesized by Eli Lilly and Company in 1968 as a potential agent to treat diabetes.[citation needed] Memantine is classified as an NMDA receptor
  17 KB (2,270 words) - 05:20, 1 May 2024
• 3-FEA
  dopamine, norepinephrine, and serotonin in the brain by acting as a releasing agent of said neurotransmitters and/or by binding to and partially blocking
  19 KB (3,317 words) - 15:23, 30 July 2022
• Alcohol
  In the past, alcohol was believed to be a non-specific pharmacological agent affecting many neurotransmitter systems in the brain. Although this notion
  95 KB (11,688 words) - 02:47, 12 May 2024
• Mephedrone
  ring. Given its chemical structure, mephedrone is likely to act as a releasing agent and a reuptake inhibitor for monoamine neurotransmitters such as dopamine
  29 KB (3,963 words) - 14:23, 16 April 2024
• 2-FEA
  that it releases the neurotransmitters: serotonin, dopamine, and norepinephrine. 2-FEA likely creates it effects by acting as a releasing agent of said
  13 KB (1,917 words) - 18:16, 30 April 2024
• 3-FMA
  substitutions at similar positions, it most likely acts primarily as a triple releasing agent of serotonin, dopamine, and norepinephrine.[citation needed] Disclaimer:
  14 KB (2,687 words) - 15:28, 30 July 2022
• 3-FPM
  consumed. Its mechanism of action appears to function by acting as a releasing agent for dopamine and norepinephrine, increasing their concentrations in
  15 KB (2,265 words) - 06:42, 8 September 2023
• 3-FA
  it most likely acts primarily as both a dopamine and norepinephrine releasing agent, with modest selectivity for serotonin. This means it effectively increases
  15 KB (2,726 words) - 11:39, 17 February 2024
• Modafinil
  which have fatigue as a symptom. Modafinil has also been used as a doping agent by various athletes due to its ability to produce physical stimulation. It
  19 KB (3,104 words) - 11:29, 16 April 2024
• 5-MAPB
  speculated that 5-MAPB acts as a releasing agent for the previously mentioned neurotransmitters. As a result, releasing agents such as 5-MAPB may exert their
  13 KB (2,233 words) - 00:32, 31 December 2022
• GHB
  so-called "rebound" effect reported by individuals using GHB as a sleeping agent wherein they awake suddenly after several hours of GHB-induced deep sleep
  35 KB (4,460 words) - 13:32, 16 April 2024
• Melatonin
  Acuña-Castroviejo, D., Camello, P. J. (2010). "Melatonin, a potential therapeutic agent for smooth muscle-related pathological conditions and aging". Current Medicinal
  15 KB (1,896 words) - 23:12, 21 April 2024

View (previous 20 | next 20) (20 | 50 | 100 | 250 | 500)